Study of new treatment plans for childhood lymphoblastic lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial studies a treatment approach for children and teens newly diagnosed with lymphoblastic lymphoma. It may help doctors choose therapies based on genetic risk information from lab testing done on tumor samples.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are under 18 years old and were newly diagnosed with lymphoblastic lymphoma
- You are being treated at a hospital/clinic that takes part in this study
- You and a parent/guardian can sign consent to join and share medical study data
- Doctors can collect and review tumor lab materials (slides/blocks) or extra fresh samples if available
- Your lymphoma is not a cancer that happened as a second cancer after another illness
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1/2 trial tests a combination of medicines (dasatinib, venetoclax, dexamethasone, cyclophosphamide, and cytarabine) in children and teens whose blood cancer has come back or did not respond to treatment. It aims to see whether this approach can control the cancer while checking what doses are safe.
This Phase 1/2 study tests a multi-drug combination (ruxolitinib, venetoclax, dexamethasone, plus chemotherapy) for children whose blood cancer has come back or did not respond. It aims to reduce the cancer by targeting specific genetic changes and may offer a new option when standard treatments have not worked.
This early-phase trial tests whether adding trametinib and dexamethasone to standard chemotherapy can improve outcomes for children whose blood cancer has come back or did not respond. Because it is a Phase 1/2 study, the main goal is to see safety and learn the best way to treat your specific cancer type.
This trial studies treatment for children and teens with certain B-cell non-Hodgkin lymphomas using a specific treatment protocol. It may help doctors confirm how well the regimen works in young patients and improve care over time.
This Phase 3 trial tests a specific treatment protocol for children and teens newly diagnosed with certain types of leukemia, aiming to improve outcomes while managing side effects. You may be invited if your child’s leukemia type and timing fit the study rules.
This trial tests a treatment plan for children with newly diagnosed acute lymphoblastic leukemia (ALL) that is considered standard-risk. It aims to see if the treatment is effective and safe.
Hear when a new Lymphoblastic Lymphoma, Childhood trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.